Inside access By Erez Klein, MD, Khashayar Farsad, MD, PhD, and John Moriarty, MD, FSIR
The summer 2024 JVIR open access articles
Two-year cumulative and functional patency after creation of endovascular arteriovenous hemodialysis fi stulae
Klein E, Rajan DJ, Maalouf T, Repko B.
Tell us about you, your research team and institution. Erez Klein, MD: I’m currently an attending physician at Moffi tt Cancer Center in Tampa, Florida. At the time of research, in 2022–2023, I was a VIR fellow at University Health Network (Toronto General, Mount Sinai Hospital Toronto, Ontario, Canada) and was honored to participate as fi rst author in this publication working under Dheeraj Rajan, MD, who has decades of experience with hemodialysis fi stulas from the IR perspective. Other personal
interests of research include patient experience during minimally invasive procedures in IR utilizing augmented reality (AR). Currently, I am establishing an AR service at Moffi tt Cancer Center IR department.
"Inside access" provides interviews and background on open access articles from the Journal of Vascular and Interventional Radiology. This issue brings you three open access articles from summer 2024. Read the full articles on
jvir.org.
28 IRQ | SUMMER 2024
What was the focus of your study? EK: The focus of our study was to evaluate the cumulative and functional patency of endovascular arteriovenous (AV) hemodialysis fistulas, specifically with the WavelinQ device. Endovascular AV fistula creations are considered new to the hemodialysis domain compared to surgical AV fistulas done prior. Our aim was to provide a good cumulative and functional patency of endovascular AV fistulas, increasing the awareness of its usage to both clinical providers and our patients.
Why did you set out to research this topic? EK: We have found that in regard to endovascular AV fistula creation, there is an insufficient amount of
literature published regarding patency. Some literature has been published in relation to methodology; however, it was important to us as a group to emphasize that endovascular AV fistula creation is a minimally invasive procedure that works, remains patent and our patients benefit from it to the highest standards. The procedure is minimally invasive, with no need for surgery. Recovery time is minimal with most patients developing an adequate fistula to be used for hemodialysis. We followed our patients and found impressive cumulative and functional capacity, as expected.
How do you think this research could impact treatment, practice or clinical processes? EK: In our opinion, endovascular AV fistula creation will become gold standard within the upcoming years. This procedure is safe, nonsurgical, has very low complication rates and has been proven to work for the majority of the patients. Furthermore, patients in need of hemodialysis who
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
